


## PHARMACEUTICAL 2020

## Chemomab Therapeutics Ltd. Rank 3 of 362





## PHARMACEUTICAL 2020



## Chemomab Therapeutics Ltd. Rank 3 of 362

The relative strengths and weaknesses of Chemomab Therapeutics Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemomab Therapeutics Ltd. compared to the market average is the variable Other Compr. Net Income, increasing the Economic Capital Ratio by 888% points. The greatest weakness of Chemomab Therapeutics Ltd. is the variable Revenues, reducing the Economic Capital Ratio by 371% points.

The company's Economic Capital Ratio, given in the ranking table, is 412%, being 715% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	18,211
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,121
Liabilities, Non-Current	725
Other Assets	1,386
Other Compr. Net Income	54,248
Other Expenses	3,350
Other Liabilities	0
Other Net Income	4,226
Property and Equipment	158
Research and Development	13,303
Revenues	0
Selling, General and Administrative Expense	6,245

Output Variable	Value in 1000 USD
Assets	19,755
Liabilities	4,846
Expenses	22,898
Stockholders Equity	14,909
Net Income	-18,672
Comprehensive Net Income	8,452
Economic Capital Ratio	412%